Drug Trial Radar · NCT06141473
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,655
Actual
Start
Dec 13, 2023
Primary completion
May 6, 2027
Study completion May 6, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration depending on the recruitment rate, the event rate, the study discontinuation rate and the 12-month minimum treatment duration. Different participants will have different study durations. The last participant randomized will have at least 12 months of study duration, and assuming a 28-month recruitment period, the first participant randomized will have 40 months or longer of study duration. * The study intervention duration will vary similarly as the study duration. * The scheduled visits will include monthly visits for the first 6 months and quarterly visits thereafter until the common end of study (EOS), or premature end of treatment (pEOT) after which 3 follow-up visits will be performed
Conditions
- Multiple Sclerosis
Interventions
FrexalimabDrug
SAR441344 Solution for IV infusion
TeriflunomideDrug
Aubagio oral tablet
Placebo infusionDrug
Solution for IV infusion
Placebo tabletDrug
Oral tablet
MRI contrast-enhancing agentsDrug
IV, as per respective label
CholestyramineDrug
oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
Activated charcoalDrug
oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapsesTime frame: Until Week 156
Locations
382 sites in 41 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 8401135
Birmingham, Alabama
North Central Neurology Associates- Site Number : 8401100
Cullman, Alabama
Alabama Neurology Associates- Site Number : 8400115
Homewood, Alabama
St. Joseph's Hospital and Medical Center- Site Number : 8401139
Phoenix, Arizona
Perseverance Research Center- Site Number : 8401138
Scottsdale, Arizona
Clinical Endpoints- Site Number : 8400050
Scottsdale, Arizona
The Neurology Center of Southern California - Carlsbad- Site Number : 8400023
Carlsbad, California
University of California Irvine - School of Medicine- Site Number : 8401143
Irvine, California
Multiple Sclerosis Center of California - Laguna Hills- Site Number : 8401122
Laguna Hills, California
Chemidox Clinical Trials- Site Number : 8401157
Lancaster, California
Hoag Memorial Hospital Presbyterian- Site Number : 8401031
Newport Beach, California
Private Practice - Dr. Regina Berkovich- Site Number : 8400005
West Hollywood, California
University of Colorado - Anschutz Medical Campus- Site Number : 8401001
Aurora, Colorado
Advanced Neurology of Colorado- Site Number : 8401148
Fort Collins, Colorado
Hartford Healthcare Medical Group- Site Number : 8401069
Norwich, Connecticut
New England Institute for Clinical Research- Site Number : 8400114
Stamford, Connecticut
MedStar Georgetown University Hospital- Site Number : 8400044
Washington D.C., District of Columbia
Neurology of Central Florida- Site Number : 8401147
Altamonte Springs, Florida
Neurology Offices of South Florida - Boca Raton- Site Number : 8401169
Boca Raton, Florida
First Choice Neurology - Espinosa Neuroscience Institute- Site Number : 8401071
Boca Raton, Florida
Nova Clinical Research - Bradenton- Site Number : 8400189
Bradenton, Florida
Mayo Clinic in Florida- Site Number : 8401093
Jacksonville, Florida
Neurology Associates - Maitland- Site Number : 8400010
Maitland, Florida
University of Miami Hospital- Site Number : 8401177
Miami, Florida
Design Neuroscience Center- Site Number : 8401191
Miami Lakes, Florida
Orlando Health Neuroscience Institute - Downtown Pavilion- Site Number : 8400060
Orlando, Florida
Axiom Clinical Research of Florida- Site Number : 8400049
Tampa, Florida
University of South Florida- Site Number : 8400013
Tampa, Florida
Palm Beach Neurology- Site Number : 8401105
West Palm Beach, Florida
Velocity Clinical Research - Savannah Neurology- Site Number : 8400061
Savannah, Georgia
Joi Life Wellness Group LLC- Site Number : 8401192
Smyrna, Georgia
NorthShore Medical Group - Evanston ( Endeavor Health)- Site Number : 8401111
Evanston, Illinois
Consultants in Neurology- Site Number : 8401020
Northbrook, Illinois
Springfield Clinic 1st - 900 Building- Site Number : 8400043
Springfield, Illinois
IU Health Physicians - Fort Wayne - Hope Drive- Site Number : 8400058
Fort Wayne, Indiana
Neuroscience Institute Center- Site Number : 8400053
Merrillville, Indiana
University of Iowa- Site Number : 8400029
Iowa City, Iowa
University of Kansas Medical Center- Site Number : 8400084
Kansas City, Kansas
Kc Research Center- Site Number : 8400032
Roeland Park, Kansas
Baptist Health Lexington- Site Number : 8401149
Lexington, Kentucky
Showing 40 of 382 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.